Clinical Trial Update: A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Lebrikizumab (LY3650150) for chronic rhinosinusitis with nasal polyps in participants treated with intranasal corticosteroid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhinosinusitis with Nasal Polyps

Drugs mentioned

• Lebrikizumab (LY3650150) (Lebrikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Phase 3 | Status: RECRUITING